TGEN Cancer Drug Development Lab

TD2 (TGen Drug Development) is a premier oncology-focused contract research organization (CRO) that provides comprehensive drug development services to biotech and pharmaceutical companies. Originally established as a subsidiary of the Translational Genomics Research Institute (TGen), the company specializes in accelerating the movement of novel cancer treatments from the laboratory to clinical approval. TD2 offers an integrated suite of services including preclinical studies, regulatory strategy, and clinical trial management, leveraging deep expertise in genomics and molecular profiling. The organization is particularly renowned for its leadership in pancreatic cancer research and its close collaboration with world-class oncologists to optimize drug development pathways. Now operating as an independent entity, TD2 continues to bridge the gap between discovery and the clinic for hard-to-treat malignancies.